Head to Head Review: NeurAxis (NRXS) versus Its Competitors

NeurAxis (NASDAQ:NRXS) is one of 75 public companies in the “Electromedical equipment” industry, but how does it weigh in compared to its rivals? We will compare NeurAxis to related companies based on the strength of its earnings, analyst recommendations, profitability, valuation, dividends, risk and institutional ownership.

Profitability

This table compares NeurAxis and its rivals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
NeurAxis	N/A	N/A	N/A
NeurAxis Competitors	-323.19%	-39.98%	-22.95%

Earnings & Valuation

This table compares NeurAxis and its rivals revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
NeurAxis	$2.46 million	-$4.78 million	-0.68
NeurAxis Competitors	$982.53 million	$86.05 million	6.38

NeurAxis’ rivals have higher revenue and earnings than NeurAxis. NeurAxis is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.

Insider & Institutional Ownership

11.8% of NeurAxis shares are owned by institutional investors. Comparatively, 45.4% of shares of all “Electromedical equipment” companies are owned by institutional investors. 14.3% of shares of all “Electromedical equipment” companies are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Analyst Recommendations

This is a summary of recent ratings and price targets for NeurAxis and its rivals, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NeurAxis	0	0	1	0	3.00
NeurAxis Competitors	229	736	1948	98	2.64

As a group, “Electromedical equipment” companies have a potential upside of 34.76%. Given NeurAxis’ rivals higher possible upside, analysts plainly believe NeurAxis has less favorable growth aspects than its rivals.

Summary

NeurAxis rivals beat NeurAxis on 6 of the 11 factors compared.

About NeurAxis

NeurAxis, Inc., a medical technology company, focuses on developing neuromodulation therapies to address chronic and debilitating conditions in children and adults in the United States. It offers IB-Stim, a percutaneous electrical nerve field stimulation system intended to be used in patients 11-18 years of age with functional abdominal pain associated with irritable bowel syndrome. The company sells its products to healthcare companies, including hospitals and clinics. The company was formerly known as Innovative Health Solutions, Inc. and changed its name to NeurAxis, Inc. in March 2022. The company was founded in 2011 and is headquartered in Carmel, Indiana.